News
AbbVie reports promising early results for novel obesity therapy ABBV-295
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
- By IPP Bureau
| March 10, 2026
Pharma powerhouse AbbVie has announced encouraging topline results from the multiple ascending dose (MAD) portion of its Phase 1 study of ABBV-295, a long-acting amylin analog targeting obesity.
The study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with a mean BMI under 30 kg/m². ABBV-295 represents a mechanistically distinct approach from existing GLP-1 and GIP receptor therapies.
The study enrolled predominantly male participants (88.3%) and tested doses ranging from 2 mg to 14 mg, with varying titration schedules and frequencies. ABBV-295 was generally well tolerated, with most adverse events being mild gastrointestinal issues occurring during the first six weeks.
Importantly, ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks. For weekly dosing groups, least-squares mean percentage reductions in body weight ranged from -7.75% to -9.79% at week 12, while every-other-week and monthly dosing groups showed reductions of -7.86% to -9.73% at week 13. Placebo groups showed negligible change.
“Obesity is a complex, chronic disease that places a substantial burden on patients, healthcare systems and society, and there remains a critical need for therapies that combine efficacy with tolerability and support long-term adherence,” said Primal Kaur, senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie.
“We are encouraged by these early results for ABBV-295, which demonstrate meaningful weight loss together with a well-tolerated safety profile. These initial results further reinforce the potential of ABBV-295 as a novel therapeutic option for people living with obesity.”
